NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Chronicling the COPD Patient Journey and Change in COPD Symptoms, Quality of Life and Exacerbations Following Initiation of Budenoside/Glycopyrronium/Formoterol [BGF]

NCT06511193

CompletedN/A

Sponsor: AstraZeneca

Conditions: Chronic Obstructive Pulmonary Disease (COPD)

Interventions: Budenoside/Glycopyrronium/Formoterol

Countries: Canada

The CHRONICLES study will investigate the change in clinical and patient reported outcomes after six-months of treatment with Budenoside/Glycopyrronium/Formoterol \[BGF\] in a real-world setting.

Eligibility overview

Sex: ALL

Age: 35 Years to 130 Years

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion Criteria:

* Physician diagnosis of COPD
* COPD patients in the Best Care Network who have a CAT score \>=10
* Age \>=35 at time of enrolment
* Minimum 12-month recorded prior medical history for patients
* Physician decision and patient agreement to initiate treatment with Breztri based on routine care (and in accordance with label and reimbursement criteria)
* Ability to read English and to provide consent to inclusion in the study

Exclusion Criteria:

* Diagnosis of asthma
* Dementia or other health issues related to memory
* Inability to use inhalers
* COPD due to documented α-1 antitrypsin deficiency
* Previous treatment with triple fixed-dose combination therapy in 12 months prior to screening visit
* Hospitalisation due to COPD exacerbation within the last 30 days prior to enrolment
* Pregnancy or lactation period
* Participation in an ongoing clinical interventional or observational trial for another COPD medication (or completed another trial within last 30 days of initiating BGF)
* Patient self-reporting or a physician record with an active COVID-19 infection at time of enrolment or hospitalized due to COVID-19 infection in the last 60 days
* Previous enrolment in this study

Locations (1)

Windsor, Ontario, Canada